Last reviewed · How we verify

Debiovision — Portfolio Competitive Intelligence Brief

Debiovision pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Sanvar® (vapreotide) Sanvar® (vapreotide) phase 3 Somatostatin analog Somatostatin receptors (SSTR2, SSTR5) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 shared drug class
  2. Camurus AB · 1 shared drug class
  3. Cedars-Sinai Medical Center · 1 shared drug class
  4. Centre Hospitalier Universitaire, Amiens · 1 shared drug class
  5. Ipsen · 1 shared drug class
  6. Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class
  7. Lahore General Hospital · 1 shared drug class
  8. Mario Negri Institute for Pharmacological Research · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Debiovision:

Cite this brief

Drug Landscape (2026). Debiovision — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/debiovision. Accessed 2026-05-13.

Related